News - MabThera, Pharmaceutical

Filter

Current filters:

MabTheraPharmaceutical

Popular Filters

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

07-11-2013

Swiss drug major Roche (ROG: SIX) has announced new data from the second stage of the CLL11 Phase III…

EuropeGazyvaMabTheraOncologyPharmaceuticalResearchRituxanRoche

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

03-10-2013

The UK’s drugs watchdog, the National Institute for Health and Care Excellence (NICE) has published…

EuropeMabTheraOncologyPharmaceuticalPricingRegulationRoche

Scottish Medicines Consortium approves MabThera for vasculitis, Lyxumia for diabetes and Targaxan for liver disease

10-09-2013

Drug regulator the Scottish Medicines Consortium (SMC) has today approved the National Health Service…

DiabetesEuropeHealthcareLyxumiaMabTheraNephrology and HepatologyNorginePharmaceuticalRocheSanofiTargaxan

German pharma watch dog finds benefits for biologicals in RA

30-08-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

New EULAR recommendations address use of synthetic and biological DMARDs

05-07-2013

The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Roche aims for expansion in Russia; Pharmsynthez production plans

20-02-2013

Swiss pharmaceutical major Roche (ROG: SIX) plans to accelerate its expansion into the Russian pharmaceutical…

EuropeMabTheraPharmaceuticalPharmsynthezProductionRoche

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

04-02-2013

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…

BiotechnologyGA101MabTheraobinutuzumabOncologyPharmaceuticalResearchRituxanRoche

New Zealand's PHARMAC decisions on Roche products

11-10-2012

PHARMAC, the pharmaceutical management agency in New Zealand, has made decisions on the proposal for…

Asia-PacificAvastinHypnovelMabTheraPharmaceuticalPricingRegulationRocheValcyte

EMA confirms Roche's MabThera made at Vacaville site poses no health risk

28-05-2012

Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…

Anti-Arthritics/RheumaticsBiotechnologyMabTheraOncologyPharmaceuticalRegulationRoche

UK NICE says Novartis MS drug Gilenya not cost effective, but backs extended use of Roche’s MabThera

01-12-2011

In further draft guidance published today (December 1), UK drugs watchdog the National Institute for…

EuropeGilenyaMabTheraNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRoche

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top